Prospective Open-Label Non-Interventional, Non-Controlled Multi Observational and Pharmaco-Economic Phase IV Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar as Well as Effectiveness, Safety and Direct Medical Costs of Nexavar Treatment Under Daily-Life Treatment Conditions.

Trial Profile

Prospective Open-Label Non-Interventional, Non-Controlled Multi Observational and Pharmaco-Economic Phase IV Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar as Well as Effectiveness, Safety and Direct Medical Costs of Nexavar Treatment Under Daily-Life Treatment Conditions.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jun 2012

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 15 Jun 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 15 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Apr 2010 Planned end date changed from 1 Apr 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top